Reinventing therapeutic antibodies
for the treatment of cancer

Fostering a culture grounded in our vision, mission and values, CytomX is an Xtraordinary clinical-stage biopharmaceutical company with a unique approach to treating cancer and a team dedicated to make a difference. We call this the CytomX Factor. CytomX has five Probody® programs in the clinic, our goal is to reinvent therapeutic antibodies for the treatment of cancer.

Watch

Yes, we can truly make a difference in the lives of patients.

We’re on it.

Read More

Vision

Transforming lives with safer, more effective therapies

Mission

Changing the treatment of cancer by urgently advancing our Probody® pipeline

Values

Integrity

We act in an honest, respectful, ethical manner

Commitment

We are dedicated to patients, CytomX, and our teammates

Creativity

Curiosity and innovation have the power to change lives

Teamwork

Together, we will succeed

Accountability

Through open communication, we hold each other to the highest possible standards

Fun

We enjoy working together and celebrating success

Xperienced executive team

CytomX is led by a seasoned executive team with deep experience in the fields of antibody drug development, cancer biology, clinical and translational medicine and business development.

Sean A. McCarthy, D. Phil.

President, Chief Executive Officer, and Chairman
Read Bio
X

Dr. McCarthy joined CytomX in December 2010 as our chief business officer and became a member of our board of directors and our president and chief executive officer in August 2011. On January 1, 2019, Dr. McCarthy became chairman of our board of directors. Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as vice president business development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of the California Life Sciences Association.

W. Michael Kavanaugh, M.D.

Chief Scientific Officer
and Head of Research
and Non-Clinical Development
Read Bio
X

Michael Kavanaugh, M.D. joined CytomX in January 2015 as chief scientific officer and head of research and early development. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF.

Amy C. Peterson, M.D.

Executive Vice President and
Chief Development Officer
Read Bio
X

Amy Peterson, M.D. joined CytomX in October 2019 as executive vice president and chief development officer. Prior to joining CytomX, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene, Ltd. where she created and led a global oncology development organization with direct medical oversight and accountability of 7 clinical assets in over thirty global trials in all phases of development in solid tumor indications. Prior to BeiGene, Dr. Peterson was vice president of clinical development at Medivation where she was primarily responsible for the development of enzalutamide (XTANDI®) and talazoparib (TALZENNA®) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. Peterson received her B.A. degree from Wesleyan University.

Danielle Olander

Senior Vice President, Talent and Systems Development
Read Bio
X

Danielle T. Olander joined CytomX in 2014, and serves as senior vice president, of talent and systems development.  She is accountable for optimizing talent, bringing organizational systems to life, and helping the organization to achieve our mission, vision, and values.  As an industry innovator, she has developed a strategic plan that includes the creation of a system for aligning our corporate goals with our business strategy that has resulted in significant growth, scalability, and sustainability.  Danielle leads the following functions for the organization: human resources, information technology, facilities, and administration.  Prior to CytomX, Danielle held leadership positions at Portola Pharmaceuticals, SuperGen (now Astex Pharmaceuticals), SUGEN (acquired by Pfizer) and Kinetic Search.  She received her B.S. in human resource management from Colorado Technical University.

Sridhar Viswanathan, Ph.D.

Senior Vice President, Process Sciences and Manufacturing Operations
Read Bio
X

Sridhar Viswanathan, Ph.D., is the senior vice president of process sciences and manufacturing operations. Dr. Viswanathan previously served as vice president of process development and manufacturing operations for Perseid Therapeutics, a joint venture between Maxygen and Astellas that was subsequently acquired by Astellas. He was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Before joining Perseid, Dr. Viswanathan spent several years at Maxygen directing process development and clinical manufacturing for next-generation biologics programs, including PEGylated interferon alpha, PEG-G-CSF and FVIIa. Prior to this, he held positions at Coulter Pharmaceutical, Bayer Corporation and Genentech. He received his doctorate in biochemistry from the University of Mississippi Medical Center and completed postdoctoral training at Rockefeller University and Stanford University.

Alison Joly, Ph.D

Senior Vice President, Program and Alliance Management
Read Bio
X

Alison Joly, Ph.D., has worked in the biotechnology sector for more than 20 years serving in multiple roles involved in oncology drug discovery, development and commercialization. Prior to joining CytomX in April 2016 as senior vice president, program and alliance management, Dr. Joly spent 14 years at Exelixis, most recently serving as vice president of program management for oncology. She oversaw multiple external partnerships relating to early and mid-stage development assets and played a critical role in the development, approval and launch of COMETRIQTM (cabozantinib) for locally advanced metastatic medullary thyroid carcinoma. Prior to Exelixis, Dr. Joly served as a scientist at Scios and CV Therapeutics. Dr. Joly holds a bachelor of science and a doctorate in biochemistry from The University of Liverpool, U.K., and completed her postdoctoral research at University of Florida and University of California, Los Angeles.

Lloyd A. Rowland, Jr.

Senior Vice President,
General Counsel, Secretary and
Chief Compliance Officer
Read Bio
X

Lloyd Rowland, Jr., joined CytomX in May 2018 as senior vice president, general counsel, secretary and chief compliance officer. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. Most recently, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

Nick Galli, J.D.

Senior Vice President, Chief Business Officer
Read Bio
X

Nick Galli, J.D. joined CytomX in February 2019. Mr. Galli most recently held the position of vice president, business development at Denali Therapeutics where he led the execution of more than twenty collaborations, including strategic partnerships with Sanofi-Genzyme, Takeda, Genentech and F-star. Prior to Denali, Mr. Galli was senior director, transactions at Johnson & Johnson Innovation Center.  Prior to this, Mr. Galli held roles of increasing responsibility at Genentech within the business development and transactional law groups. Mr. Galli began his career as a corporate attorney at the law offices of Skadden, Arps, Slate, Meagher & Flom and practiced in the technology transactions group at Wilson Sonsini Goodrich & Rosati. Mr. Galli received his B.A. degree from Princeton University and his J.D. from the Georgetown University Law Center.

 

Alison L. Hannah, M.D.

Chief Medical Officer
Read Bio
X

Alison L. Hannah, M.D. joined as senior vice president and chief medical officer. Dr. Hannah brings 30 years of experience in the development of investigational cancer therapies having most recently served as a consultant to nearly 30 pharmaceutical and biotechnology companies. In this capacity, Dr. Hannah has successfully filed over 40 regulatory applications for First-in-Human clinical testing, and has played significant roles in the broad marketing approval of 8 therapeutics (talazoparib, enzalutamide, defibrotide, carfilzomib, sunitinib, toceranib, irinotecan and filgrastim) including extensive experience interacting with global health and regulatory authorities. Earlier in her career, Dr. Hannah held the role of Senior Medical Director at SUGEN, Inc. (acquired by Pharmacia & Upjohn, now Pfizer) where she had oversight of clinical development, clinical operations, and pharmacovigilance. At SUGEN, she specialized in the development of tyrosine kinase inhibitors, including sunitinib (SUTENT) for kidney cancer. Dr. Hannah began her career at Quintiles, a global contract research organization, where she specialized in overseeing early to registrational-stage oncology clinical trials. Dr. Hannah currently serves on the board of NeoGenomics, a publicly traded cancer diagnostic company. Dr. Hannah received her B.A in biochemistry and immunology from Harvard University and her M.D. from the University of Saint Andrews.

Carlos Campoy

Senior Vice President and Chief Financial Officer
Read Bio
X

Mr. Campoy brings over 30 years of financial and leadership experience, the majority from publicly held companies within the healthcare and biopharmaceutical sectors. Most recently, Mr. Campoy held the position of chief financial officer at Alder BioPharmaceuticals, which was acquired in October 2019 by Lundbeck A/S, where he led the finance organization and readied the company for commercial launch of its lead program, eptinezumab, a recently approved treatment for the prevention of migraine.  Prior to Alder, Mr. Campoy held the role of vice president of finance, international at Allergan plc. Prior to joining Allergan, over the course of an 18-year tenure at Eli Lilly and Company, Mr. Campoy held senior financial leadership positions including most recently as chief financial officer of Eli Lilly Japan K.K.  Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil. Mr. Campoy holds a Certified Management Accountant (CMA) designation.

Xemplary Board of Directors

Sean A. McCarthy, D. Phil.

President, Chief Executive Officer, and Chairman

READ BIO

Dr. McCarthy joined CytomX in December 2010 as our chief business officer and became a member of our board of directors and our president and chief executive officer in August 2011. On January 1, 2019, Dr. McCarthy became chairman of our board of directors. Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as vice president business development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of the California Life Sciences Association.

Charles S. Fuchs, M.D., M.P.H.

Director

READ BIO

Charles S. Fuchs, M.D., M.P.H., is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development, and conducts research assessing novel therapeutic approaches in oncology. Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.

Fred Gluck

Co-Founder and Director

READ BIO

Fred Gluck is a former managing partner (chief executive) of McKinsey & Company Inc. After retiring from McKinsey in 1995, he joined the Bechtel Group, where he served as vice chairman and director. He later rejoined McKinsey & Company as a consultant until retiring again in July 2003. Mr. Gluck was the founding chairman and CEO of both CytomX and Cynvenio Biosystems and continues to serve as chairman of Cynvenio. He also serves as director of a number of eleemosynary organizations, including the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). He recently retired from the Board of Amgen and was the presiding director of HCA (Hospital Corporation of America). Mr. Gluck received his B.S. from Manhattan College and an M.S. from New York University: both degrees in electrical engineering.

Elaine V. Jones, Ph.D.

Director

READ BIO

Dr. Elaine Jones retired in April 2019 from her role as vice president, worldwide business development and senior partner at Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer Ventures as executive director in 2008, Dr. Jones was responsible for making and managing venture investments for Pfizer as well as serving in Board roles for several and therapeutic companies. Prior to this, Dr. Jones held the position of general partner at EuclidSR Partners, a venture firm specializing in private investment in public equity within the health sciences, healthcare, biopharmaceutical sectors. Dr. Jones began her investing career in 1999 at S.R. One, the corporate investment fund of GlaxoSmithKline. Prior to this, Dr. Jones served as director of scientific licensing at SmithKline Beecham and as a research scientist in the research and development division of SmithKline Beecham Pharmaceutical. During her venture career, Dr. Jones has served on the boards of more than 20 early to mid-stage biotechnology, therapeutic and pharmaceutical companies. Dr. Jones currently serves as a member of the board of directors of Gritstone Oncology and NextCure. Dr. Jones holds a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh.

James R. Meyers

Director

READ BIO

James R. Meyers brings more than 30 years of worldwide commercial leadership experience within the biotechnology industry. Mr. Meyers has served as a Senior Advisor to Gilead Sciences since his retirement from Gilead in February 2018. Prior to his advisory role, Mr. Meyers most recently served as Gilead’s executive vice president of worldwide commercial operations where he was responsible for all commercial activities including pricing and market access in North America, Europe, Middle East, Australia and Japan. Over his 22-year career at Gilead, Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. Mr. Meyers currently serves on the Board of Arbutus Biopharma Corporation, a public biopharmaceutical company focused on commercializing a cure for patients suffering from chronic hepatitis B infection. Mr. Meyers holds a B.S. in Economics from Boston College.

John Scarlett, M.D.

Director

READ BIO

John “Chip” A. Scarlett currently serves as chief executive officer, president and a member of the board of directors of Geron Corporation. Since February 2015, Dr. Scarlett has also served as a member of the board of directors of Chiasma, Inc. Prior to joining Geron in 2011, Dr. Scarlett served as president, chief executive officer and a member of the board of directors of Proteolix, Inc., from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From February 2002 until its acquisition by Ipsen, S.A., in October 2008, Dr. Scarlett served as founder, chief executive officer and a member of the board of directors of Tercica, Inc., and also as its president from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as president and chief executive officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as senior vice president of medical and scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine.

Matthew Young

Director

READ BIO

Matthew P. Young was appointed chief operating officer and chief financial officer of GRAIL in October 2019. Prior to joining GRAIL, Mr. Young served as executive vice president and chief financial officer of Jazz Pharmaceuticals a role he held since February 2015. He previously had served as senior vice president and chief financial officer of Jazz since March 2014 and as senior vice president, corporate development of Jazz since April 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, he served as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and a M.B.A. from the Wharton School of the University of Pennsylvania.

Xpert Scientific Advisory Board

Lisa Butterfield, Ph.D.

Vice President of the Parker Institute for Cancer Immunotherapy Research Center and Adjunct Professor of Microbiology and Immunology

University of California, San Francisco

READ BIO

Lisa H. Butterfield, PhD, is the Vice President of the PICI Research Center, and an Adjunct Professor of Microbiology and Immunology at the University of California, San Francisco. She is focused on cancer vaccines and cellular therapies. Butterfield was most recently Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh (2003-2018) and Director of the Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory. She holds a PhD in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. She is the President of the Society of Immunotherapy of Cancer (SITC, 2017-2018) and a member of the SITC Executive Committee (2015-2020). She led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group (2006-2018). She investigates immunotherapy for hepatocellular cancer and melanoma, involving peptides, dendritic cells and adenoviruses, and effector responses to tumor antigens. She has published over 150 peer-reviewed manuscripts, reviews and book chapters, and mentored over 20 students and postdocs.

Lisa Coussens, Ph.D.

Hildegard Lamfrom Endowed Chair in Basic Science Professor, Chairwoman, Department of Cell, Developmental & Cancer Biology, and Associate Director for Basic Research, Knight Cancer Institute

Oregon Health & Science University

READ BIO

Dr. Coussens is the Chair of the Department of Cell, Developmental & Cancer Biology, and Associate Director for Basic Research in the Knight Cancer Institute at Oregon Health & Sciences University (OHSU) and holds the Hildegard Lamfrom Chair in Basic Science.  She received her Ph.D. in Biological Chemistry from UCLA in 1993, and completed her postdoctoral fellowship in Cancer Biology at UCSF in Douglas Hanahans’ laboratory.  Dr. Coussens research focus is on elucidating the roles of immune cells and their mediators as critical regulators of solid tumor development.  Her lab reported that lymphocytes selectively regulate myeloid cell functions in mouse models of squamous and mammary carcinoma, mesothelioma, and pancreatic adenocarcinoma, and that selective inhibition of key factors regulating either myeloid recruitment or function significantly enhances efficacy of chemo- and radiation therapy, and thereby extend long term survival of tumor-bearing mice.  These discoveries are currently being translated into the clinical realm; Dr. Coussens is Lead PI on a KOMEN Promise grant conducting an investigator-initiated multi-center Phase Ib/II clinical trial evaluating a novel macrophage-antagonist in combination with chemotherapy in women with metastatic triple negative breast cancer.  More recently, Dr. Coussens was awarded a Stand Up To Cancer – Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research grant focused on clinical evaluation of immune-based therapies in pancreas cancer.  Her contributions to this international team are based on her laboratories identification of B cells and humoral immune-mediated factors regulating T cells and immune suppression in squamous and pancreas cancer.  Specifically, her studies are supporting evaluation of a Bruton’s tyrosine kinase (BTK) inhibitor plus chemotherapy in Phase Ib/II clinical trials of pancreatic cancer and Head and Neck cancer patients.  Dr. Coussens has received the prestigious Gertrude B. Elion Award from the American Association of Cancer Research (AACR), the Mallinckrodt Award for Medical Science, a V Foundation Scholar Award, and two sequential Era of Hope Scholar Awards from the Department of Defense Breast Cancer Research Program.  In 2012, she was the recipient of the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship, and the 2015 recipient of the 13th Rosalind E. Franklin Award from the National Cancer Institute.

John Lambert, Ph.D.

Consultant/Scientific Advisor

Honorary Professor, Queen’s University Belfast, Northern Ireland, UK

READ BIO

Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then earned a Ph.D. in Biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham. Dr Lambert’s postdoctoral training was at the University of California, Davis (1976-1980), working on ribosome structure in the laboratory of Dr Robert R. Traut, and at the University of Glasgow, Scotland (1980-1982), working on the arom multienzyme complex in the laboratory of Dr John R. Coggins.  In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics.  Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts.  After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement.  During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development.  One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. Dr Lambert is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).  In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.

Charles Sentman, Ph.D.

Professor of Microbiology and Immuniology and Director, Center for Synthetic Immunity

Dartmouth Medical School

READ BIO

Charles Sentman is a Professor in the Department of Microbiology & Immunology at the Geisel School of Medicine at Dartmouth and the Director of the Center for Synthetic Immunity. Dr. Sentman’s research interests are natural killer (NK) cell recognition mechanisms, the role of NK cells as a part of the immune defense against cancer and infection, and how NK cell and T-cell effector mechanisms affect the tumor microenvironment. His laboratory is focused on the development of novel immunotherapy strategies for cancer, and there are several major areas of research: chimeric antigen receptor-based immunotherapy, bi-specific engager targeting of tumors, and development of novel signaling platforms for cell-based therapies. Earlier in his career, Dr. Sentman worked as a team leader and section leader at AstraZeneca R&D in Lund, Sweden. Dr. Sentman received a B.S. from the University of Illinois and a Ph.D. from the University of Texas Southwestern Medical Center. He completed postdoctoral training at Washington University and the Karolinska Institute.

Louis Weiner, M.D.

Professor, Francis L. & Charlotte G. Gragnani Chair of Oncology, Director of Georgetown Lombardi Comprehensive Cancer Center, and Director of the MedStar Georgetown Cancer Institute

Georgetown University Medical Center

READ BIO

Dr. Louis Weiner is director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani Chair and is professor of oncology and chair of the Department of Oncology at Georgetown University Medical Center. He also serves as the Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington DC and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction. Prior to joining Georgetown Lombardi as director in 2008, Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia, PA, and also served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR), and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and the Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award.Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston. 

"One small step for CytomX, one huge step for mankind in the fight against cancer."

—Lori Carman